Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

AE-941 (AEterna).

Keith Dredge1

  • 1Centre for Immunology and Cancer Research, Princess Alexandra Hospital, Ipswich Road, Woolloongabba, Brisbane, QLD 4102, Australia. kdredge@cicr.uq.edu.au

Current Opinion in Investigational Drugs (London, England : 2000)
|July 10, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intraoperative drug delivery to hindbrain tumours via an injectable hydrogel is well tolerated and confers survival benefit against atypical teratoid/rhabdoid xenografts.

Drug delivery and translational research·2026
Same author

PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction.

Oncogene·2023
Same author

Phase Ib open-label, multicenter study of pixatimod, an activator of TLR9, in combination with nivolumab in subjects with microsatellite-stable metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma and other solid tumors.

Journal for immunotherapy of cancer·2023
Same author

Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike-ACE2 Interaction.

ACS central science·2022
Same author

A netrin domain-containing protein secreted by the human hookworm Necator americanus protects against CD4 T cell transfer colitis.

Translational research : the journal of laboratory and clinical medicine·2021
Same author

Sulfated glycolipid PG545 induces endoplasmic reticulum stress and augments autophagic flux by enhancing anticancer chemotherapy efficacy in endometrial cancer.

Biochemical pharmacology·2020
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

AEterna is developing AE-941, an angiogenesis inhibitor from shark cartilage, for non-small-cell lung cancer treatment. This compound inhibits key enzymes and growth factors involved in tumor development.

Area of Science:

  • Oncology
  • Biochemistry
  • Pharmacology

Background:

  • Angiogenesis is crucial for tumor growth and metastasis.
  • Matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) play key roles in angiogenesis.
  • Non-small-cell lung cancer (NSCLC) is a major cause of cancer-related mortality, necessitating novel therapeutic strategies.

Purpose of the Study:

  • To evaluate AE-941, an angiogenesis inhibitor derived from shark cartilage, as a potential treatment for non-small-cell lung cancer.
  • To investigate the inhibitory properties of AE-941 against MMP-2, MMP-9, and VEGF.

Main Methods:

  • AE-941 is derived from the ultrafiltration of liquid shark cartilage.
  • In vitro assays were used to assess the inhibitory effects of AE-941 on MMP-2, MMP-9, and VEGF.

Related Experiment Videos

Main Results:

  • AE-941 demonstrated inhibitory properties against MMP-2, MMP-9, and VEGF.
  • These findings suggest a potential anti-angiogenic mechanism of action for AE-941.

Conclusions:

  • AE-941 exhibits anti-angiogenic potential through the inhibition of key enzymes and growth factors.
  • AE-941 represents a promising candidate for the treatment of non-small-cell lung cancer.